Bibliography
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72(10):1613-20
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72(10):1605-12
- Kang YS, Moon HH, Lee SE, et al. Clinical Experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: A Case Series. Dig Dis Sci 2014
- Best WR, Becktel JM, Singleton JW, Kern FJr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70(3):439-44
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317(26):1625-9
- Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20(1):27-32
- Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340(18):1398-405
- Online G. Generics and Biosimilars Initiative. Efficacy, extrapolation and interchangeability of biosimilars. 2014. Available from: www.gabionline.net/Biosimilars/Research/Efficacy-extrapolation-and interchangeability-of-biosimilars [Last accessed 01 June 2015]
- Online G. Generics and Biosimilars Initiative. Extrapolation of biosimilar infliximab indications to inflammatory bowel disease. 2014. Available from: www.gabionline.net/Biosimilars/Research/Extrapolation-of-biosimilar-infliximab-indications-to-inflammatory-bowel-disease [Last accessed 01 June 2015]
- Online G. Generics and Biosimilars Initiative. ABPI issues updated position paper on biosimilars. 2014. Available from: www.gabionline.net/Biosimilars/General/ABPI-issues-updated-position-paper-on-biosimilars [Last accessed 01 June 2015]
- Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53(10):1471-8
- Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131(3):719-28
- van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63(1):72-9
- Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014;15(Suppl 1):S65-71
- Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7(7):586-9
- McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs 2014;28(3):313-21
- Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J Crohns Colitis 2014;8(11):1548-50